key: cord-0863047-dg89cwz3 authors: Doležalová, Karolína; Tuková, Jana; Pohunek, Petr title: The respiratory consequences of COVID‐19 lasted for a median of 4 months in a cohort of children aged 2–18 years of age date: 2022-02-24 journal: Acta Paediatr DOI: 10.1111/apa.16297 sha: 1c1a722b0b371a9cd87b7fcba4dc078d9d3fc39b doc_id: 863047 cord_uid: dg89cwz3 AIM: We focused on the clinical picture, severity and prognosis of children who experienced long‐term respiratory issues after COVID‐19. METHODS: This was a national Czech multicentre study of paediatric post‐COVID syndrome, which used a standard protocol to evaluate structural and functional anomalies and exclude alternative diagnoses. From 6 January to 30 June 2021, 11 paediatric pulmonologists enrolled all paediatric referrals aged 2–18 years with persistent respiratory symptoms more than 12 weeks after COVID‐19, namely cough, dyspnoea and chest pain. Medical histories were taken, and physical examinations, lung function testing, chest X‐ray and blood tests were performed. RESULTS: The dominant symptoms in the 39 children (56.4% girls) were exertional dyspnoea (76.9%) and a chronic cough (48.7%), while dyspnoea at rest (30.8%) and chest pain (17.9%) were less prevalent. More than half (53.8%) reported more than 1 symptom, and 38.5% had abnormal results for 1 of the following tests: lung function, chest X‐ray or D‐dimers. The median age of the children was 13.5 years (interquartile range ±4.8 years), and the median recovery time was 4 months (range 1.5–8 months). CONCLUSION: Our initial data suggest that the long‐term respiratory impact of COVID‐19 was relatively mild in our cohort, with a favourable prognosis. for more than 12 weeks after acute COVID-19 and could not be explained by any alternative diagnosis. 4 A meta-analysis by Fernandez et al showed that more than 60% of patients infected by SARS-CoV-2 presented with post-COVID-19 symptoms. 5 Fatigue and dyspnoea were the most prevalent symptoms, particularly 60 days and at least 90 days after COVID-19, with a pooled prevalence that ranged from 35% to 60%, depending on the follow-up period. Other post-COVID-19 symptoms included a cough (20-25%), loss of smell (10-20%) , loss of taste (15-20%) and joint pain (15-20%) . 5 Another study, by Shah et al, stated that common long-term COVID-19 symptoms were fever, pain and neurological, cardiovascular, gastrointestinal, dermatological and musculoskeletal symptoms. 6 Although a meta-analysis by Behnood et al indicated a lower incidence and severity of acute paediatric COVID-19, 7 greater attention is now being paid to severe complications following infections in paediatric populations. These include multisystem inflammatory syndrome in children, which is also known as paediatric inflammatory multisystem syndrome temporarily associated with SARS-CoV-2. 8 This syndrome develops within four weeks of exposure to the SARS-CoV-2 virus, regardless of whether COVID-19 takes a symptomatic or asymptomatic course. It has been associated with a high risk of multiorgan failure, especially with severe cardiac involvement. Only limited data regarding the incidence, clinical picture, diagnosis, therapy or prognosis of paediatric post-COVID are available. These have included several case series that focused on parents who contacted a physician about their children as a result of discussions on a social media forum 9 and surveys carried out on patients by paediatric departments. 10 They have also included cohorts of randomly selected school classes with population-based seronegative control groups, 11 single-centre cohorts examined by phone calls and outpatient assessments 12 and a prospective cohort study based on self-data reporting by a mobile application. 13 The aim of our study was to explore the clinical picture, severity and prognosis of post-COVID syndrome in children, with a particular focus on the respiratory system. Children were referred to, and followed up by, the national network for Czech paediatric pulmonologists. In addition, we suggested a uniform panel of screening tests to maintain an identical procedure between all of the centres. The goal of this diagnostic battery was to use currently available techniques to explore possible structural and functional anomalies of the respiratory tract in paediatric patients with post-COVID syndrome. This prospective, national observational study focused on centres for paediatric pulmonology that covered all the regions of the Czech Republic. Four centres of paediatric pulmonology in Prague participated in this study, together with one centre in each of the 7 regions outside the capital. However, it is probably that these centres did not cover the whole Czech paediatric population, because limited capacity in larger remote regions means that fewer children are referred to specialists. From 6 January to 30 June 2021, 11 paediatric pulmonologists enrolled all children aged 2-18 years with persistent respiratory symptoms after COVID-19. The patients had all been referred by paediatricians working in inpatient or outpatient settings ( Figure 1 ). The inclusion criteria comprised three key elements. First, the presence of dyspnoea, at rest or on exertion, a cough or chest pain for 12 weeks or more after being infected with SARS-CoV-2. Second, documentation of a previous SARS-CoV-2 infection, confirmed by a positive polymerase chain reaction test and/or the detection of a significant elevation of antibodies. Third, the absence of any pre-existing chronic respiratory disease. A standard protocol was put in place to evaluate structural and functional anomalies and exclude alternative diagnoses. The medical histories of the children were taken during the first consultation with the patient and their parents, in accordance with current best practice. Standardised questionnaires were not used. Symptoms were both self-reported and reported by the child's parents. The patients then underwent a physical examination, plain chest radiograph, blood tests and lung function tests, which comprised spirometry, diffusing capacity and the 6-minute walk test. The laboratory tests comprised a blood count, basic biochemistry and allergy panel, Ddimer levels and SARS-CoV-2 antibodies. If the initial panel showed that the children had abnormal results, we considered an extended spectrum of investigative methods. This included the following: a chest ultrasound, a spiral chest computed tomography (CT) scan with high-resolution reconstruction, CT pulmonary angiograms and a ventilation/perfusion lung scan. The subjects were invited to attend at least two outpatient visits over a 6-month period. There were possible risks during the data collection that post-COVID symptoms could be confused with, or overlap with, bronchial asthma, even if the child had not been diagnosed with this disease. Children with suspected bronchial asthma usually had a positive family history, atopic history, positive allergy panel and an excellent response to anti-asthmatic treatment. We placed these in an asthmatic subgroup. However, such patients would have needed a longer follow-up to reach a final diagnosis of asthma. During the data analysis, we observed other striking differences in the post-COVID cohort, in relation to their medical histories, whether they played sport and the presence of concomitant • This Czech multicentre study focused on 39 children aged 2-18 who experienced long-term respiratory issues after COVID-19. • The dominant symptoms were exertional dyspnoea (76.9%) and a chronic cough (48.7%), while dyspnoea at rest (30.8%) and chest pain (17.9%) were less prevalent. • The long-term respiratory impact of COVID-19 was relatively mild in our cohort, who had a median age of 13.5 years and a median recovery time of 4 months. non-respiratory symptoms. In addition to the asthmatic subgroup, we decided to establish three more possible post-COVID subgroups: standard, polymorphous and sporty. The standard subgroup was the dominant category and it comprised children with the expected respiratory symptomatology of cough, dyspnoea and fatigue. The subjects in the polymorphous subgroup described a wide variety of symptoms, in addition to the respiratory symptomatology. These included headaches, difficulties concentrating, anxiety, hair loss, chest pain, a cough, dyspnoea and tachycardia. We also noticed that the symptoms showed different characteristics in the sporty subgroup. These children were used to high-intensity physical activities and the key issue that they reported was worsening of their physical performance. We compared numerical variables using one-way analysis of variance and categorical variables with Fisher's exact test. All analyses were performed using SPSS Statistics, version 21 (IBM, New We examined 67 children and 40 fulfilled the inclusion criteria. One refused to participate and the other 39 were included in the study ( Figure 1 ). All the children had a mild acute course of COVID-19. One 18-year-old girl with haemoptysis, which was an unusual symptom, was hospitalised for 5 days, but she did not require ventilatory support or oxygen therapy ( Table 1) . None of the subjects had been diagnosed with multisystem inflammatory syndrome in children. The dominant symptoms were exertional dyspnoea (76.9%) and a chronic cough (48.7%), while dyspnoea at rest (30.8%) and chest pain (17.9%) were less prevalent ( Table 2 ). More than half of the children (53.8%) reported more than 1 symptom. We found that 38.5% had abnormal results for 1 of the following tests, lung function, chest X-ray or D-dimers, and 7.7% had abnormal results for 2 of those tests. There were no associations between any symptoms and abnormal results. We suspected that 9 of the subjects had incipient bronchial asthma, which was related to COVID-19, based on their personal and family histories, spirometry, laboratory results and the therapeutic effects of asthma treatment. However, no statistically significant differences in symptoms or laboratory and functional abnormalities were found between the standard, asthmatic, sporty and polymorphous subgroups. This was despite their different post-COVID clinical manifestations. We followed up 34 of the 39 subjects for the whole duration of our 6-month study: 1 was lost to follow-up and the other 4 were followed up for less than 6 months. These 34 patients experienced complete remission of their tracked symptoms within 1.5 to 8 months and the median recovery time was 4 months ( Table 3) Table 2 ). This study shows that the 39 children in our cohort had relatively mild and limited respiratory consequences as a result of COVID-19. There are several results from our research that are particularly worth highlighting. tachycardia. This group was probably under-reported, due to selection bias in this study. In addition, a number of non-respiratory problems may lead to patients being referred to other specialists rather than pulmonologists. We also noticed that the symptoms had different characteristics in the sporty subgroup. These children were used to regular high-intensity physical activities, and they said that their worsening physical performance was the dominant symptom. Children who do not engage in regular sporting activities could have missed discrete symptoms of exertional dyspnoea. TA B L E 1 Details and clinical data of 3 unusual cases who underwent chest CTs or ventilation/perfusion scan imaging To our knowledge, this was the first prospectively planned study that focused on the respiratory aspects of paediatric post-COVID symptoms. Our data suggest a lower risk of functional lung impairment in children, compared to the published data for adults. 14,15 The strengths of our study were that it was carried out following a peak in the country's pandemic in the early months of 2021 and the centres who took part collected data from all regions of the Czech Republic. In fact, the country had one of the highest COVID-19-related mortality rates worldwide in March 2021. 16 Our study was based on 2.3 million confirmed SARS-CoV-2 infections by mid-December 2021 and children and adolescents represented 10-15% of those cases. 2 This provided an adequately large sample for monitoring paediatric post-COVID syndrome. The main limitations of this study were the differences in the laboratory equipment and software used by the centres and the rather short follow-up period. However, this was necessary so that we could publish these results in a timely manner. A major limitation of the study was the relatively small number of patients that were included, even though this was a national study. Our initial data suggest that the long-term respiratory impact of COVID-19 appeared to be relatively mild in our cohort, with a favourable prognosis. Further studies with more subjects and longer follow-up periods are needed. The test panel that we designed seemed to be effective for evaluating the structural and functional abnormalities of the respiratory tract in paediatric post-COVID syndrome. COVID-19 in the Czech Republic according to age CoVdata Trained Immunity: a Tool for Reducing Susceptibility to and the Severity of SARS-CoV-2 Infection Long COVID or post-COVID-19 syndrome: putative pathophysiology, risk factors, and treatments Prevalence of post-COVID-19 symptoms in hospitalized and non-hospitalized COVID-19 survivors: A systematic review and meta-analysis Managing the long term effects of covid-19: summary of NICE, SIGN, and RCGP rapid guideline Persistent symptoms following SARS-CoV-2 infection amongst children and young people: A meta-analysis of controlled and uncontrolled studies Multisystem inflammatory syndrome (MIS-C): a systematic review and meta-analysis of clinical characteristics, treatment, and outcomes Case report and systematic review suggest that children may experience similar long-term effects to adults after clinical COVID-19 Pediatric long-COVID: An overlooked phenomenon? Long-term Symptoms After SARS-CoV-2 Infection in Children and Adolescents Preliminary evidence on long COVID in children Illness duration and symptom profile in symptomatic UK school-aged children tested for SARS-CoV-2. The Lancet Child & Adolescent Respiratory function in patients post-infection by COVID-19: a systematic review and meta-analysis Phenotyping long COVID Czechia: Coronavirus Pandemic Country Profile -Our World in Data We thank the colleagues who assisted us with patient recruit- The authors have no conflicts of interests to declare. https://orcid.org/0000-0001-7786-8105Jana Tuková https://orcid.org/0000-0001-6655-1073Petr Pohunek https://orcid.org/0000-0003-4557-2515